Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT04949932 Completed - Acne Vulgaris Clinical Trials

Application of Poly-herbal Powder for Treating Acne Vulgaris

Start date: April 3, 2021
Phase: N/A
Study type: Interventional

Acne is a common problem in adolescence to young adult. But there is no such remedy available for acne treatment which has no side effects. Different types of herbs powder has been using in patients with acne vulgaris in the traditional practice of Indian subcontinent as single form or compound. Scientific evidence have shown many herbs has no known side effects and effective on acne. These herbs have antibacterial, anti-inflammatory and anti-oxidant effects. So, This study is intended to find out an inexpensive and safe alternative by using some common herbs such as Azadirachta indica, Curcuma longa, Lens culinaris Mentha arvensis and Trigonella foenum-graecum. The aim of the study is to evaluate the clinical efficacy of Poly herbal powder (PHP) for treating patients with acne vulgaris. Total of 42 adults with acne vulgaris was recruited for this study. Study subjects was included both of male and female with age limit of 18 to 35 years. Duration of study is 05 months with "day one advertisement" for screening followed by randomization for the treatment. The duration of active participation of each study subject was 3 consecutive weeks or 21days. Difference of baseline and post intervention mean by Total lesion Count (TLC) compared with placebo and assesses the % of reduction of acne based on The Global Acne Grading System (GAGS) score. Safety assessment was obtained from the incidence and type of adverse events during study period.

NCT ID: NCT04943159 Completed - Acne Vulgaris Clinical Trials

Afamelanotide in Patients Suffering With Acne Vulgaris

Start date: August 24, 2010
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the effect of afamelanotide on the facial inflammatory acne-related lesions in patients with mild to moderate acne vulgaris, including tolerability of afamelanotide by patients with moderate acne vulgaris and effects of the treatment on quality of life in eligible patients.

NCT ID: NCT04940767 Completed - Acne Vulgaris Clinical Trials

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

Start date: June 28, 2021
Phase: Phase 4
Study type: Interventional

Acne vulgaris is a common disease of both males and females, usually manifesting initially during adolescence. The use of retinoic acid analogues such as adapalene, tazarotene and isotretinoin are also commonly prescribed to treat inflammation; dysregulated sebum production and comedonal acne. This study seeks to evaluate the efficacy and safety of concomitant use of both AMZEEQ® and oral isotretinoin compared to oral isotretinoin only use and to explore sequence dosing of both products as part of a long-term management protocol for acne vulgaris.

NCT ID: NCT04937374 Completed - Acne Vulgaris Clinical Trials

Efficacy and Tolerability of Rehmannia Glutinosa Leaf Extract in the Treatment of Acne Vulgaris

Start date: June 5, 2021
Phase: N/A
Study type: Interventional

In this study, The Investigator will be assessing the efficacy and tolerability of Rehmannia glutinosa Libosch leaf-based extract formulation consumption on the treatment of Acne Vulgaris in a randomized, double-blind, placebo-controlled study for the duration of 56 days.

NCT ID: NCT04899843 Completed - Acne Vulgaris Clinical Trials

Effectiveness of Zinc Supplementation With Topical Retinoids in Acne Vulgaris Patients

Start date: April 27, 2021
Phase: Phase 2
Study type: Interventional

The study was 8 weeks, randomized, double-blind, placebo-controlled trial to assess the effect of zinc sulphate on symptoms of mild and moderate acne vulgaris in 122 patients. Participants was assessed at baseline, and 8 weeks. Subjects was randomized to receive either 20 mg elemental zinc daily or 20 mg placebo tablet daily for 8 weeks. The primary outcome was the measure of the GAGS score and the secondary measure includes serum zinc level and evaluate adverse effects.

NCT ID: NCT04892706 Completed - Acne Vulgaris Clinical Trials

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Start date: June 11, 2021
Phase: Phase 2
Study type: Interventional

The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.

NCT ID: NCT04883736 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Start date: August 31, 2020
Phase: Early Phase 1
Study type: Interventional

To demonstrate the therapeutic equivalence and safety of Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.

NCT ID: NCT04873089 Completed - Acne Clinical Trials

Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin

Start date: September 17, 2018
Phase:
Study type: Observational

The aim of this study is to evaluate, at different times, the RV3278A - ET0943 cosmetic product efficacy after 8 weeks of application on the face (twice-daily application). At T1 (Baseline), T2 (4 weeks) and T3 (8 weeks), the following assessments are performed: - The reduction of the pilosebaceous follicular ostium size in vivo (pores) on the forehead - The clinical evaluation (count of non inflammatory and inflammatory acne lesions, IGA score) of the face - The reduction in visible follicles - The standardized numerical photographs of face and ¾ right and left profile in normal, parallel polarized, cross polarized and UV light - The analysis of the skin lipids of the forehead - The qualitative and quantitative analysis of the sebum and comedones constituents (nose wings) This is a comparative, open-labelled study, on subjects with oily and acne prone skins on the face. Each group includes 18 subjects.

NCT ID: NCT04870489 Active, not recruiting - Acne Vulgaris Clinical Trials

Combined Treatment With CO2 Laser and Isotretinoin for Acne Scars

Start date: November 1, 2017
Phase: Phase 2
Study type: Interventional

Isotretinoin is an FDA-approved vitamin A metabolite for the treatment of severe acne; acne that does not respond to other treatments and has a tendency to cause scarring. Ablative laser treatment is another effective treatment against acne scarring. We believe that the combination of CO2 ablative laser treatment with oral isotretinoin for the treatment of scarring is not only safer but also more effective and leads to much more successful cosmetic results.

NCT ID: NCT04856917 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris